Page 43 - Trials Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19 Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19 DURHAM, N.C., Jan. 25, 2021 — Researchers from the COVID-19 Prevention Network (CoVPN) announced that the monoclonal antibody (mAb), LY-CoV555 (bamlanivimab), evaluated in a Phase III trial significantly reduces the risk of contracting symptomatic COVID-19 as well as reduces the clinical course of COVID-19 in study participants who did become symptomatic. The study, CoVPN 3501, was condu...

For the first time, researchers say infusions of antibodies can prevent HIV infection Source: Corey L, et al. Abstract 1480. Presented at: HIV Research for Prevention; Jan. 27-28 and Feb. 3-4, 2021 (virtual meeting). Disclosures: Fauci reports no relevant financial disclosures. Healio could not confirm financial disclosures for Corey or Mgodi at the time of publishing. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ...

Share A large study in 11 countries tested whether infusions of monoclonal antibodies against HIV could protect people from infection. HIV Vaccine Trials Network Labmade antibodies can prevent HIV infection—but only if they match the virus Jan. 26, 2021 , 10:05 AM It has taken more than 4 years and $119 million for HIV researchers to test whether giving people infusions of antibodies made in a lab can protect them from the AIDS virus. Now, the unsatisfying answer is in: sometimes. People who were given infusions of the monoclonal antibodies every 8 weeks had a 75% lower risk of beco...

Cancer patients and the COVID-19 vaccines Clinicians, cancer patients and coronavirus researchers weigh in on vaccination safety, timing, allergy concerns and more January 14, 2021 • By Diane Mapes / Fred Hutch News Service Metastatic breast cancer patient and family doctor Dr. Carla Kakuta of Winters, California, receives her first COVID-19 shot, before heading off to cancer treatment. "I went straight from vaccination to the infusion center because I’m awesome like that," she wrote on Twitter. “I've been seeing patients in person through t...

Through the Ride Health platform, a study coordinator can request rides on behalf of participants. (Ride Health) Access to private transportation, or lack thereof, has long been a barrier to participation in clinical trials. And COVID-19 isn’t making things easier, with public health guidelines discouraging the use of public transport and ride-hailing services setting up policies against passengers with COVID-19 symptoms. So, how are institutions running COVID-19 trials getting patients in for site visits? New York-based Ride Health is on the job. The company is partnering with ACTI...